Through AFTRiC, the CAI has expanded what is already one of Australia’s most comprehensive suites of preclinical and clinical imaging research instruments. Credit: The University of Queensland.

The Centre for Advanced Imaging (CAI) of the University of Queensland in Australia has unveiled a new facility to develop therapies for cancer.

The Australian Cancer Research Foundation (ACRF) Facility for Targeted Radiometals in Cancer (AFTRiC) was established with a $1.2m grant from the ACRF.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The facility will focus on the assessment and development of new “alpha therapies” that can destroy cancer without impacting healthy tissue.

Under the government’s National Collaborative Research Infrastructure Scheme (NCRIS), the National Imaging Facility (NIF) made a $1.2m investment while the Ian Potter Foundation and the University of Queensland provided additional funding.

This grant was also supported by industry partners, including Telix Pharmaceuticals.

CAI was one of three beneficiaries of ACRF grant funds to commence new cancer research in 2021.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CAI deputy director (research) Professor Kris Thurecht stated: “Radiopharmaceuticals and theranostics have been identified by all levels of government as a next-generation research priority, and AFTRiC firmly positions us as one of the country’s leading capabilities in this space.

“We will be one of the few places in the country that can produce these specialised isotopes and, in collaboration with our industry partners, we will evaluate and hopefully develop clinical grade products for clinical trials.”

AFTRiC is expected to accelerate the development of new cancer treatments for academic and commercial partners.